Solu-Medrol (Methylprednisolone Sod Succ/PF) Patent Expiration, LOE Window & CMS Spending

Solu-Medrol (Methylprednisolone Sod Succ/PF) by Pfizer: Off-Patent Genericized (AB Competition), 0 AB generics, $21.5M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$21.5M
2024 Medicare Part D Spend$330K
2024 Medicaid Spend$21.2M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 24.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.